A Phase I Investigation of MK5108 and MK5108 With Docetaxel in Patients With Advanced Solid Tumours.

Trial Profile

A Phase I Investigation of MK5108 and MK5108 With Docetaxel in Patients With Advanced Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Docetaxel; MK 5108
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Dec 2015 According to an article published in the Investigational New Drugs, this study has been terminated early due to toxicities in Panel2 at MK-5108 doses below the anticipated PK exposure target.
    • 01 Dec 2015 Results published in the Investigational New Drugs
    • 27 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top